大洋生物(003017.SZ)发预增，预计前三季度归母净利润7400万元至9000万元，同比增长44.35% 至75.56%

Core Viewpoint - The company, Dayang Bio (003017.SZ), anticipates a significant increase in net profit for the first three quarters of 2025, driven by rising demand for its main products, potassium carbonate and veterinary raw materials [1] Financial Performance - The company expects net profit attributable to shareholders to be between 74 million and 90 million yuan, representing a year-on-year growth of 44.35% to 75.56% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 67 million and 82 million yuan, indicating a year-on-year increase of 39.04% to 70.17% [1] Market Factors - The increase in net profit is primarily attributed to market influences that have boosted the demand for the company's main products [1] - Both sales volume and prices of potassium carbonate and veterinary raw materials have risen compared to the same period last year, contributing to the improved gross margin [1]